Aromatase, aromatase inhibitors, and breast cancer
Tóm tắt
Từ khóa
Tài liệu tham khảo
McDonnell, 2002, Connections and regulation of the human estrogen receptor, Science, 296, 1642, 10.1126/science.1071884
Kuiper, 1996, Cloning of a novel receptor expressed in rat prostate and ovary, Proc. Natl. Acad. Sci. U.S.A., 93, 5925, 10.1073/pnas.93.12.5925
Couse, 1999, Estrogen receptor null mice: what have we learned and where will they lead us?, Endocr. Rev., 20, 358, 10.1210/edrv.20.3.0370
McDonnell, 1999, The molecular pharmacology of SERMs, Trends Endocrinol. Metab., 10, 301, 10.1016/S1043-2760(99)00177-0
Musgrove, 2009, Biological determinants of endocrine resistance in breast cancer, Nat. Rev. Cancer, 9, 631, 10.1038/nrc2713
Beatson, 1896, On the treatment of inoperable cases of carcinoma of themamma. Suggestions for a new method of treatment with illustrative cases, Lancet, II, 104, 10.1016/S0140-6736(01)72307-0
Love, 2002, Oophorectomy for breast cancer: history revisited, J. Natl. Cancer Inst., 94, 1433, 10.1093/jnci/94.19.1433
Jordan, 2007, Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer, Steroids, 72, 7, 10.1016/j.steroids.2006.10.009
Fisher, 1994, Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14, J. Natl. Cancer Inst., 86, 527, 10.1093/jnci/86.7.527
Jordan, 1995, Tamoxifen: toxicities and drug resistance during the treatment and prevention of breast cancer, Annu. Rev. Pharmacol. Toxicol., 35, 195, 10.1146/annurev.pa.35.040195.001211
Schwarzel, 1973, Studies on the mechanism of estrogen biosynthesis. 8. The development of inhibitors of the enzyme system in human placenta, Endocrinology, 92, 866, 10.1210/endo-92-3-866
Macedo, 2009, Aromatase inhibitors and breast cancer, Ann. N. Y. Acad. Sci., 1155, 162, 10.1111/j.1749-6632.2008.03689.x
Brodie, 1977, The effect of an aromatase inhibitor 4-hydroxy-4-androstene-3,17-dione, on estrogen-dependent processes in reproduction and breast cancer, Endocrinology, 100, 1684, 10.1210/endo-100-6-1684
R.J. Santen, H. Brodie, E.R. Simpson, P.K. Siiteri, A. Brodie, History of aromatase: saga of an important biological mediator and therapeutic target, Endocr. Rev. 30(4) 343–375.
Brodie, 1981, Inactivation of aromatase in vitro by 4-hydroxy-4-androstene-3 17-dione and 4-acetoxy-4-androstene-3,17-dione and sustained effects in vivo, Steroids, 38, 693, 10.1016/0039-128X(81)90087-8
H.J. Burstein, A.A. Prestrud, J. Seidenfeld, H. Anderson, T.A. Buchholz, N.E. Davidson, K.E. Gelmon, S.H. Giordano, C.A. Hudis, J. Malin, E.P. Mamounas, D. Rowden, A.J. Solky, M.R. Sowers, V. Stearns, E.P. Winer, M.R. Somerfield, J.J. Griggs, American society of clinical oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer, J. Clin. Oncol.
Thompson, 1974, Utilization of oxygen and reduced nicotinamide adenine dinucleotide phosphate by human placental microsomes during aromatization of androstenedione, J. Biol. Chem., 249, 5364, 10.1016/S0021-9258(20)79735-8
Chen, 1988, Human aromatase: cDNA cloning, Southern blot analysis, and assignment of the gene to chromosome 15, DNA, 7, 27, 10.1089/dna.1988.7.27
M. Akhtar, J.N. Wright, P. Lee-Robichaud, A review of mechanistic studies on aromatase (CYP19) and 17alpha-hydroxylase-17,20-lyase (CYP17), J. Steroid Biochem. Mol. Biol.
Harada, 1997, Aberrant expression of aromatase in breast cancer tissues, J. Steroid Biochem. Mol. Biol., 61, 175, 10.1016/S0960-0760(97)80010-6
Valladares, 1979, Induction of testicular aromatization by luteinizing hormone in mature rats, Endocrinology, 105, 431, 10.1210/endo-105-2-431
Reed, 1976, Kinetic properties of human placental aromatase. Application of an assay measuring 3H2O release from 1beta,2beta-3H-androgens, J. Biol. Chem., 251, 1625, 10.1016/S0021-9258(17)33694-3
Durham, 1985, Regulation of aromatase activity of rat granulosa cells: induction of synthesis of NADPH-cytochrome P-450 reductase by FSH and dibutyryl cyclic AMP, Mol. Cell Endocrinol., 40, 211, 10.1016/0303-7207(85)90177-7
Hahn, 1985, 19-Hydroxylation of androgens in the rat brain, Proc. Natl. Acad. Sci. U.S.A., 82, 2728, 10.1073/pnas.82.9.2728
Simpson, 1994, Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis, Endocr. Rev., 15, 342
Sebastian, 2001, A highly complex organization of the regulatory region of the human CYP19 (aromatase) gene revealed by the Human Genome Project, J. Clin. Endocrinol. Metab., 86, 4600, 10.1210/jcem.86.10.7947
Amarneh, 1993, Functional domains of human aromatase cytochrome P450 characterized by linear alignment and site-directed mutagenesis, Mol. Endocrinol., 7, 1617
Kellis, 1987, Purification and characterization of human placental aromatase cytochrome P-450, J. Biol. Chem., 262, 4413, 10.1016/S0021-9258(18)61364-X
Lephart, 1990, The structure of cDNA clones encoding the aromatase P-450 isolated from a rat Leydig cell tumor line demonstrates differential processing of aromatase mRNA in rat ovary and a neoplastic cell line, Mol. Cell Endocrinol., 70, 31, 10.1016/0303-7207(90)90056-E
Karkola, 2007, A three-dimensional model of CYP19 aromatase for structure-based drug design, J. Steroid Biochem. Mol. Biol., 105, 63, 10.1016/j.jsbmb.2006.11.023
Kao, 1996, Binding characteristics of seven inhibitors of human aromatase: a site-directed mutagenesis study, Cancer Res., 56, 3451
Ghosh, 2009, Structural basis for androgen specificity and oestrogen synthesis in human aromatase, Nature, 457, 219, 10.1038/nature07614
D. Ghosh, J. Griswold, M. Erman, W. Pangborn, X-ray structure of human aromatase reveals an androgen-specific active site, J. Steroid Biochem. Mol. Biol. 118(4–5) 197–202.
Smith, 2003, Aromatase inhibitors in breast cancer, N. Engl. J. Med., 348, 2431, 10.1056/NEJMra023246
Geisler, 2002, Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study, J. Clin. Oncol., 20, 751, 10.1200/JCO.2002.20.3.751
Bonneterre, 2001, Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma, Cancer, 92, 2247, 10.1002/1097-0142(20011101)92:9<2247::AID-CNCR1570>3.0.CO;2-Y
Nabholtz, 2000, Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group, J. Clin. Oncol., 18, 3758, 10.1200/JCO.2000.18.22.3758
Mouridsen, 2004, Aromatase inhibitors in advanced breast cancer, Semin. Oncol., 31, 3, 10.1053/j.seminoncol.2004.09.020
Bonneterre, 2000, Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex randomized group efficacy and tolerability study, J. Clin. Oncol., 18, 3748, 10.1200/JCO.2000.18.22.3748
Mouridsen, 2001, Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group, J. Clin. Oncol., 19, 2596, 10.1200/JCO.2001.19.10.2596
Paridaens, 2004, First line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients: a randomized phase III trial of the EORTC Breast Group, Proc. Am. Soc. Clin. Oncol., 6
Buzdar, 2001, Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate, J. Clin. Oncol., 19, 3357, 10.1200/JCO.2001.19.14.3357
Buzdar, 1996, Anastrozole: a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group, J. Clin. Oncol., 14, 2000, 10.1200/JCO.1996.14.7.2000
Dombernowsky, 1998, Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate, J. Clin. Oncol., 16, 453, 10.1200/JCO.1998.16.2.453
Kaufmann, 2000, Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group, J. Clin. Oncol., 18, 1399, 10.1200/JCO.2000.18.7.1399
Goss, 1999, Randomized phase III trial comparing the new potent and selective third-generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients. North American Vorozole Study Group, J. Clin. Oncol., 17, 52, 10.1200/JCO.1999.17.1.52
Forbes, 2008, Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial, Lancet Oncol., 9, 45, 10.1016/S1470-2045(07)70385-6
Thurlimann, 2005, A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer, N. Engl. J. Med., 353, 2747, 10.1056/NEJMoa052258
Mouridsen, 2009, Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer, N. Engl. J. Med., 361, 766, 10.1056/NEJMoa0810818
Gnant, 2009, Endocrine therapy plus zoledronic acid in premenopausal breast cancer, N. Engl. J. Med., 360, 679, 10.1056/NEJMoa0806285
Lin, 2008, Advances in adjuvant endocrine therapy for postmenopausal women, J. Clin. Oncol., 26, 798, 10.1200/JCO.2007.15.0946
Jakesz, 2005, The benefits of sequencing adjuvant tamoxifen and anastrozole in postmenopausal women with hormone responsive early breast cancer: 5 year-analysis of ABCSG trial 8
Kaufmann, 2007, Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 study, J. Clin. Oncol., 25, 2664, 10.1200/JCO.2006.08.8054
Boccardo, 2006, Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial, Ann. Oncol., 17, 10, 10.1093/annonc/mdl941
Coombes, 2007, Survival and safety of exemestane versus tamoxifen after 2–3 years’ tamoxifen treatment (Intergroup Exemestane study): a randomised controlled trial, Lancet, 369, 559, 10.1016/S0140-6736(07)60200-1
Rea, 2009, Five years of exemestane as initial therapy compared to 5 years of tamoxifen followed by exemestane: The TEAM trial, a prospective, randomized, phase III trial in postmenopausal women with hormone-sensitive early breast cancer
Stewart, 2001, Scottish adjuvant tamoxifen trial: a randomized study updated to 15 years, J. Natl. Cancer Inst., 93, 456, 10.1093/jnci/93.6.456
Fisher, 2001, Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial, J. Natl. Cancer Inst., 93, 684, 10.1093/jnci/93.9.684
Peto, 2007, ATLAS (Adjuvant Tamoxifen, Longer Against Shorter): international randomized trial of 10 versus 5 years of adjuvant tamoxifen among 11,500 women – preliminary results
Jakesz, 2007, Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a, J. Natl. Cancer Inst., 99, 1845, 10.1093/jnci/djm246
Goss, 2007, Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17, J. Clin. Oncol., 25, 2006, 10.1200/JCO.2006.09.4482
Mamounas, 2008, Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial, J. Clin. Oncol., 26, 1965, 10.1200/JCO.2007.14.0228
Smith, 2001, Preoperative/neoadjuvant medical therapy for early breast cancer, Lancet Oncol., 2, 561, 10.1016/S1470-2045(01)00490-9
Smith, 2005, Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial, J. Clin. Oncol., 23, 5108, 10.1200/JCO.2005.04.005
Cataliotti, 2006, Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative “Arimidex” compared to Tamoxifen (PROACT) trial, Cancer, 106, 2095, 10.1002/cncr.21872
Eiermann, 2001, Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study, Ann. Oncol., 12, 1527, 10.1023/A:1013128213451
Thurlimann, 1997, Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase II multicentre multinational study. Exemestane Study Group, Eur. J. Cancer, 33, 1767, 10.1016/S0959-8049(97)00283-9
Carlini, 2001, Formestane, a steroidal aromatase inhibitor after failure of non-steroidal aromatase inhibitors (anastrozole and letrozole): is a clinical benefit still achievable?, Ann. Oncol., 12, 1539, 10.1023/A:1013180214359
Miller, 2008, Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter?, Oncologist, 13, 829, 10.1634/theoncologist.2008-0055
Geisler, 1996, Treatment with formestane alone and in combination with aminoglutethimide in heavily pretreated breast cancer patients: clinical and endocrine effects, Eur. J. Cancer, 32A, 789, 10.1016/0959-8049(95)00623-0
Harper-Wynne, 1999, Randomized trial to compare the efficacy and toxicity of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) with methotrexate mitoxantrone (MM) in advanced carcinoma of the breast, Br. J. Cancer, 81, 316, 10.1038/sj.bjc.6990694
Bertelli, 2005, Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer, Oncology, 69, 471, 10.1159/000090985
Zilembo, 2004, The estrogen suppression after sequential treatment with formestane in advanced breast cancer patients, Biomed. Pharmacother., 58, 255, 10.1016/j.biopha.2003.12.009
Chia, 2008, Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT, J. Clin. Oncol., 26, 1664, 10.1200/JCO.2007.13.5822
M.E. Hammond, D.F. Hayes, M. Dowsett, D.C. Allred, K.L. Hagerty, S. Badve, P.L. Fitzgibbons, G. Francis, N.S. Goldstein, M. Hayes, D.G. Hicks, S. Lester, R. Love, P.B. Mangu, L. McShane, K. Miller, C.K. Osborne, S. Paik, J. Perlmutter, A. Rhodes, H. Sasano, J.N. Schwartz, F.C. Sweep, S. Taube, E.E. Torlakovic, P. Valenstein, G. Viale, D. Visscher, T. Wheeler, R.B. Williams, J.L. Wittliff, A.C. Wolff, American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer, J. Clin. Oncol. 28(16) 2784–2795.
Elledge, 2000, Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study, Int. J. Cancer, 89, 111, 10.1002/(SICI)1097-0215(20000320)89:2<111::AID-IJC2>3.0.CO;2-W
Lockwood, 1999, A simple index using video image analysis to predict disease outcome in primary breast cancer, Int. J. Cancer, 84, 203, 10.1002/(SICI)1097-0215(19990621)84:3<203::AID-IJC1>3.0.CO;2-U
Ferguson, 1995, Demethylation of the estrogen receptor gene in estrogen receptor-negative breast cancer cells can reactivate estrogen receptor gene expression, Cancer Res., 55, 2279
Ottaviano, 1994, Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells, Cancer Res., 54, 2552
Sharma, 2006, Restoration of tamoxifen sensitivity in estrogen receptor-negative breast cancer cells: tamoxifen-bound reactivated ER recruits distinctive corepressor complexes, Cancer Res., 66, 6370, 10.1158/0008-5472.CAN-06-0402
Yang, 2000, Transcriptional activation of estrogen receptor alpha in human breast cancer cells by histone deacetylase inhibition, Cancer Res., 60, 6890
Yang, 2001, Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells, Cancer Res., 61, 7025
Sabnis, 2008, Upregulation of ERα and aromatase by HDACi MS-275 in an ER negative breast cancer xenograft model
Sabnis, 2008, Combination of HDACi entinostat (SNDX-275) with letrozole in provides superior control over tumor growth in MDA-MB-231 xenograft model
Sabnis, 2007, HDAC inhibitors sensitize ER negative breast cancer cells to AIs
Macedo, 2008, Preclinical modeling of endocrine response and resistance: focus on aromatase inhibitors, Cancer, 112, 679, 10.1002/cncr.23191
Jelovac, 2005, Activation of mitogen-activated protein kinase in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole, Cancer Res., 65, 5380, 10.1158/0008-5472.CAN-04-4502
Clarke, 2003, Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling, Oncogene, 22, 7316, 10.1038/sj.onc.1206937
Shi, 2009, Expression of ER-{alpha}36, a novel variant of estrogen receptor {alpha}, and resistance to tamoxifen treatment in breast cancer, J. Clin. Oncol., 27, 3423, 10.1200/JCO.2008.17.2254
Schiff, 2000, Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo, J. Natl. Cancer Inst., 92, 1926, 10.1093/jnci/92.23.1926
Zhou, 2007, Enhanced NF kappa B and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer, BMC Cancer, 7, 59, 10.1186/1471-2407-7-59
G. Sabnis, O. Goloubeva, R. Gilani, L. Macedo, A. Brodie, Sensitivity to the aromatase inhibitor letrozole is prolonged after a “break” in treatment, Mol. Cancer Ther. 9(1) 46–56.
Macedo, 2008, Combination of anastrozole with fulvestrant in the intratumoral aromatase xenograft model, Cancer Res., 68, 3516, 10.1158/0008-5472.CAN-07-6807
Kato, 1995, Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase, Science, 270, 1491, 10.1126/science.270.5241.1491
Joel, 1998, Estradiol-induced phosphorylation of serine 118 in the estrogen receptor is independent of p42/p44 mitogen-activated protein kinase, J. Biol. Chem., 273, 13317, 10.1074/jbc.273.21.13317
Chen, 2002, Phosphorylation of human estrogen receptor alpha at serine 118 by two distinct signal transduction pathways revealed by phosphorylation-specific antisera, Oncogene, 21, 4921, 10.1038/sj.onc.1205420
Johnston, 2009, Enhancing the efficacy of hormonal agents with selected targeted agents, Clin. Breast Cancer, 9, S28, 10.3816/CBC.2009.s.003
Wu, 2004, Selective phosphorylations of the SRC-3/AIB1 coactivator integrate genomic reponses to multiple cellular signaling pathways, Mol. Cell, 15, 937, 10.1016/j.molcel.2004.08.019
Font de Mora, 2000, AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor, Mol. Cell Biol., 20, 5041, 10.1128/MCB.20.14.5041-5047.2000
Sabnis, 2008, Stopping treatment can reverse acquired resistance to letrozole, Cancer Res., 68, 4518, 10.1158/0008-5472.CAN-07-5999
Sabnis, 2009, Trastuzumab reverses letrozole resistance and amplifies the sensitivity of breast cancer cells to estrogen, Cancer Res., 69, 1416, 10.1158/0008-5472.CAN-08-0857
Sabnis, 2007, Inhibition of the phosphatidylinositol 3-kinase/Akt pathway improves response of long-term estrogen-deprived breast cancer xenografts to antiestrogens, Clin. Cancer Res., 13, 2751, 10.1158/1078-0432.CCR-06-2466
Lipton, 2005, Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy, Cancer, 104, 257, 10.1002/cncr.21202
Lipton, 2008, HER-2 protein expression predicts response to trastuzumab in FISH-positive patients with metastatic breast cancer
Marcom, 2007, The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers, Breast Cancer Res. Treat., 102, 43, 10.1007/s10549-006-9307-8
Mackey, 2006, Trastuzumab prolongs progression-free survival in hormone-dependent and HER2-positive metastatic breast cancer, Breast Cancer Res. Treat., 100